Vitacost has moved well over the last one year. The improvement in fundamentals and the expected turnaround is having a positive impact on the stock. Despite a bit of correction in the market, the stock has appreciated over the last one month. It is around 40% up on a 52 week basis, and is 70% above the 52 week low made in August. The expectation is that the losses may reduce and the company may turnaround over the next few quarters. The appreciation has perhaps priced in a lot of future positives, but the strength in the stock cannot be ignored. It is around its 52 week highs. So it may be a good idea to keep tagging along with the stock with an exit strategy or a trailing stop loss in mind. $8.70 will be a crucial hurdle to cross, and that should be kept in mind. The next earnings may be a risky exposure, and should be played carefully. Apart from the margins, Vitacost also needs to focus on high growth products to bolster revenue growth. For this, potential products from other companies may be targeted. The third party products contribute three-quarters to the sales, and if it is able to identify some good potential products at the right stage, it may be able to get good deals. Such products will help in growth and improve the margins. There are several new launches in the market from time to time. Chromadex Corporation (CDXC) recently launched a vitamin Nicotinamide Riboside which is being considered a high potential product. It can look at any product which is in line with its existing or planned focus segment. The strength of the stock indicates that it will take off if the company reports net profit in the next few quarters. On the other hand, slippages will not be taken too kindly.